Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Indianapolis-based Eli Lilly and Co. said today that it has closed its acquisition of ImClone Systems Inc., a New York-based developer of cancer drugs.
Lilly paid $70 in cash for each share of ImClone in a deal worth about $6.3 billion.
Lilly outbid New York rival Bristol-Myers Squibb Co., but analysts question whether Lilly will make enough money from the cancer drugs to make the expensive acquisition profitable.
Please enable JavaScript to view this content.
Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.